Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Bloody Mysteries of Ribosomes.

Sulima SO, De Keersmaecker K.

Hemasphere. 2018 Oct;2(5):e95. doi: 10.1097/HS9.0000000000000095. Epub 2018 Oct 2. No abstract available.

2.

Cancer Biogenesis in Ribosomopathies.

Sulima SO, Kampen KR, De Keersmaecker K.

Cells. 2019 Mar 11;8(3). pii: E229. doi: 10.3390/cells8030229. Review.

3.

Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Fancello L, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Mar 8. doi: 10.1038/s41375-019-0424-x. [Epub ahead of print]

PMID:
30850735
4.

Ribosomal Lesions Promote Oncogenic Mutagenesis.

Sulima SO, Kampen KR, Vereecke S, Pepe D, Fancello L, Verbeeck J, Dinman JD, De Keersmaecker K.

Cancer Res. 2019 Jan 15;79(2):320-327. doi: 10.1158/0008-5472.CAN-18-1987. Epub 2018 Nov 27.

PMID:
30482776
5.

Rise of the specialized onco-ribosomes.

Kampen KR, Sulima SO, De Keersmaecker K.

Oncotarget. 2018 Oct 16;9(81):35205-35206. doi: 10.18632/oncotarget.26231. eCollection 2018 Oct 16. No abstract available.

6.

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Feb;33(2):319-332. doi: 10.1038/s41375-018-0176-z. Epub 2018 Jun 21. Erratum in: Leukemia. 2019 Mar 8;:.

7.

Ribosomal proteins: a novel class of oncogenic drivers.

Sulima SO, De Keersmaecker K.

Oncotarget. 2017 Sep 11;8(52):89427-89428. doi: 10.18632/oncotarget.20802. eCollection 2017 Oct 27. No abstract available.

8.

How Ribosomes Translate Cancer.

Sulima SO, Hofman IJF, De Keersmaecker K, Dinman JD.

Cancer Discov. 2017 Oct;7(10):1069-1087. doi: 10.1158/2159-8290.CD-17-0550. Epub 2017 Sep 18. Review.

9.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

10.

Ribosomopathies and the paradox of cellular hypo- to hyperproliferation.

De Keersmaecker K, Sulima SO, Dinman JD.

Blood. 2015 Feb 26;125(9):1377-82. doi: 10.1182/blood-2014-10-569616. Epub 2015 Jan 9.

11.

Ribosomal frameshifting in the CCR5 mRNA is regulated by miRNAs and the NMD pathway.

Belew AT, Meskauskas A, Musalgaonkar S, Advani VM, Sulima SO, Kasprzak WK, Shapiro BA, Dinman JD.

Nature. 2014 Aug 21;512(7514):265-9. doi: 10.1038/nature13429. Epub 2014 Jul 9.

12.

Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis.

Sulima SO, Patchett S, Advani VM, De Keersmaecker K, Johnson AW, Dinman JD.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5640-5. doi: 10.1073/pnas.1400247111. Epub 2014 Mar 31.

13.

Eukaryotic rpL10 drives ribosomal rotation.

Sulima SO, G├╝lay SP, Anjos M, Patchett S, Meskauskas A, Johnson AW, Dinman JD.

Nucleic Acids Res. 2014 Feb;42(3):2049-63. doi: 10.1093/nar/gkt1107. Epub 2013 Nov 8.

Supplemental Content

Loading ...
Support Center